Cagrilintide on TikTok: What day-2 diaries leave out
Quick answer
The creator self-administered cagrilintide at 0.5 mg then added 0.25 mg the same day, reaching 0.75 mg total on day 1, and reported severe fatigue, difficulty swallowing, and exercise impairment on day 2. These symptoms are consistent with too-rapid dose escalation of an amylin analogue, not with expected therapeutic appetite suppression as described in published trials. Cagrilintide remains investigational with no FDA approval, and the sourcing and dosing approach described here falls outside any supervised clinical protocol.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @callmekt1 actually say?
On day 2 of using cagrilintide, the creator described feeling unusually fatigued, having difficulty swallowing liquids, "felt like somebody was sitting on my face" after waking up, and struggled to get out of bed for 30 minutes. They dosed 0.5 mg, then added 0.25 mg the same day to reach roughly 0.75 mg (750 micrograms), and reported the drink they made for pre-workout was "hard to get down." They were honest enough to admit it's too early to draw conclusions, which is worth crediting. The self-titration happened within a single day, which is a detail that matters a lot clinically.
They also casually used the term "suppression" to describe the experience, framing side effects as appetite suppression rather than tolerability issues. That framing is where things start to get shaky.
Does the science back this up?
Fatigue and nausea are real, documented side effects of cagrilintide, especially early in dosing. But difficulty swallowing is not a standard symptom in the clinical trial literature, and the self-titration approach used here runs counter to how this compound has been studied.
Cagrilintide is a long-acting amylin analogue being developed by Novo Nordisk, studied most extensively in the OASIS and CagriSema trials. In the phase 2 CagriSema trial (Enebo et al., 2021, The Lancet), nausea, vomiting, and decreased appetite were the most common adverse events during dose escalation. Fatigue appeared in some participants but was not among the top-reported effects. Difficulty swallowing (dysphagia) does not appear as a primary adverse event in published cagrilintide data. The phase 3 REDEFINE 1 trial (Knop et al., 2025, NEJM) confirmed nausea and vomiting as the dominant tolerability concerns, particularly when titrating too quickly. The creator's same-day dose addition, going from 0.5 mg to 0.75 mg in one day, is not a protocol used in any published trial.
What did they get wrong (or right)?
Credit where it's due: they correctly identified that day 2 is too early to draw conclusions, and they said so on camera. That's more self-awareness than most peptide content on TikTok manages.
What they got wrong is the framing. Calling difficulty drinking tea and extreme fatigue "the type of suppression that Cagrilintide gives" conflates side effects with therapeutic effect. Appetite suppression and tolerability side effects are not the same thing. Nausea makes food unappealing. That's not the same mechanism as amylin-mediated satiety signaling. Lumping them together misleads viewers into thinking suffering through these symptoms is just how the drug works. It isn't. The other problem is the dosing approach. Adding a second injection the same day to "stack" toward 0.75 mg is not how cagrilintide has been evaluated in any trial. Published protocols use weekly escalation over several months (Knop et al., 2025, NEJM). Self-titrating within a single day increases the likelihood of the exact symptoms described here.
What should you actually know?
Cagrilintide is not FDA-approved as of mid-2025. It is an investigational amylin analogue that has shown meaningful weight loss results in combination with semaglutide in clinical trials, but it is not available through legitimate pharmacies in the United States. Anyone sourcing it outside of a clinical trial is getting a research chemical of unverified purity and potency.
The symptoms described, especially fatigue severe enough to spend 30 minutes unable to get out of bed and difficulty swallowing liquids, are not trivial and should not be normalized as "suppression." Dysphagia in particular has other explanations worth ruling out. If you are on a regulated telehealth platform and experiencing difficulty swallowing on any injectable medication, that warrants a conversation with your provider, not a day 2 TikTok update. The lack of any mention of medical supervision in this video is the most important thing missing from the conversation.
- Cagrilintide is investigational. No FDA-approved version exists yet.
- Self-adjusting doses within a single day is not supported by clinical trial protocols.
- Difficulty swallowing is not a standard documented side effect and should not be dismissed.
- Fatigue is documented but usually mild in controlled, supervised dosing schedules.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 5 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Cagrilintide on TikTok: What day-2 diaries leave out, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference
A broad meta-analysis anchor for GLP-1 weight-loss effect and class-level comparisons.
PubMed
Discontinuing glucagon-like peptide-1 receptor agonists and body habitus
Used for pages discussing stopping therapy, weight regain, and long-term planning.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
Cagrilintide on TikTok: What day-2 diaries leave out is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
Compare providers, services and access requirements in the directory before contacting a suitable care team.
Helpful context before the funnel
Claim verdict
The useful answer behind this video
Claim being checked
The creator self-administered cagrilintide at 0.
FormBlends verdict
The creator self-administered cagrilintide at 0.5 mg then added 0.25 mg the same day, reaching 0.75 mg total on day 1, and reported severe fatigue, difficulty swallowing, and exercise impairment on day 2. These symptoms are consistent with too-rapid dose escalation of an amylin analogue, not with expected therapeutic appetite suppression as described in published trials. Cagrilintide remains investigational with no FDA approval, and the sourcing and dosing approach described here falls outside any supervised clinical protocol.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- The creator self-administered cagrilintide at 0.5 mg then added 0.25 mg the same day, reaching 0.75 mg total on day 1, and reported severe fatigue, difficulty swallowing, and exercise impairment on day 2. These symptoms are consistent with too-rapid dose escalation of an amylin analogue, not with expected therapeutic appetite suppression as described in published trials. Cagrilintide remains investigational with no FDA approval, and the sourcing and dosing approach described here falls outside any supervised clinical protocol.
- Cagrilintide has no FDA approval as of mid-2025. Anyone using it outside a clinical trial is sourcing an unregulated research compound.
- Phase 3 REDEFINE 1 trial data (Knop et al., 2025, NEJM) show nausea and vomiting as the primary tolerability issues, not difficulty swallowing or severe fatigue at properly titrated doses.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- Cagrilintide has no FDA approval as of mid-2025. Anyone using it outside a clinical trial is sourcing an unregulated research compound.
- Phase 3 REDEFINE 1 trial data (Knop et al., 2025, NEJM) show nausea and vomiting as the primary tolerability issues, not difficulty swallowing or severe fatigue at properly titrated doses.
- Same-day dose stacking from 0.5 mg to 0.75 mg is not a protocol used in any published cagrilintide trial and likely contributed to the symptoms described.
- Side effects that make food or liquids hard to consume are not the same as amylin-mediated satiety signaling. Suffering through tolerability problems is not a sign the drug is working.
- Difficulty swallowing liquids is not listed as a standard adverse event in cagrilintide phase 2 or phase 3 trial publications and should not be dismissed or self-managed.
- The CagriSema combination trial (Enebo et al., 2021, The Lancet) used multi-week titration schedules. Compressing that escalation into hours changes the risk profile entirely.
- No mention of medical supervision appears in this video. Any injectable peptide, especially an investigational one, warrants provider oversight before and during use.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
K.T.T. · TikTok creator
32.4K views on this video
So this is my day 2 update on Cagrilintide. I'll let ya"ll know if I made it thru the day. #cagrilintide #peptidetherapy #ratatouille #glowupinprogress #peppers
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by K.T.T., not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.